BIOTRICITY INC. DL-,001

Biotricity reported a 10.2% revenue increase in Q3 2026 to $4.0 million and an improved gross profit margin of 81.5%; net loss narrowed to $1.1 million. The company also posted a positive EBITDA of $280,000 for the third consecutive quarter and plans product expansions and international approvals. Despite the progress, the share price recently fell 16.05% to $0.286 and is close to its 52-week low, signaling investors’ concerns about future profitability. » More on de.investing.com

Biotricity reports Q2 2026 revenue up 19% to $3.9 million and gross profit of $3.2 million (+29.4%). Gross margin improved to 81.9% and the company achieved positive EBITDA for the second consecutive quarter at $373,000, with a reduced net loss of $772,000. The stock rose 7.89% after the results; Biotricity plans an FDA filing for a new multiparametric cardiac monitor by the end of Q1 next year and aims for further profitability. » More on de.investing.com

Biotricity reports a first positive EBITDA of $333,000 for Q1 2026, with revenue up 21% to $3.9 million and a gross margin of 80.5%. Net loss narrowed significantly to $754,000; management cites partnerships with Amazon AWS and Google TensorFlow and is pursuing FDA approval and international expansion. » More on de.investing.com